Under the terms of the transaction, Catalent acquires Bone Therapeutics’ cell therapy manufacturing subsidiary, SCTS, for gross proceeds of €12 million... Nov 18
Clinical evidence for this device demonstrates safety and efficacy for people suffering from mitral regurgitation... Nov 18
-Advertisements-